These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 15093180)
1. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Sova P; Ren XW; Ni S; Bernt KM; Mi J; Kiviat N; Lieber A Mol Ther; 2004 Apr; 9(4):496-509. PubMed ID: 15093180 [TBL] [Abstract][Full Text] [Related]
2. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Wohlfahrt ME; Beard BC; Lieber A; Kiem HP Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719 [TBL] [Abstract][Full Text] [Related]
3. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304 [TBL] [Abstract][Full Text] [Related]
4. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383 [TBL] [Abstract][Full Text] [Related]
5. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins. Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548 [TBL] [Abstract][Full Text] [Related]
6. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route. Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824 [TBL] [Abstract][Full Text] [Related]
7. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism]. Tang YX; Chen Y; Gu JF; Qi R; Zou WG; Jiang LL; Liu XY Ai Zheng; 2005 May; 24(5):536-42. PubMed ID: 15890093 [TBL] [Abstract][Full Text] [Related]
8. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Bernt KM; Ni S; Tieu AT; Lieber A Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826 [TBL] [Abstract][Full Text] [Related]
9. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713 [TBL] [Abstract][Full Text] [Related]
10. Adenovirus E1A reverses the resistance of normal primary human lung fibroblast cells to TRAIL through DR5 upregulation and caspase 8-dependent pathway. Zhu H; Ling W; Hu B; Su Y; Qiu S; Xiao W; Qi Y Cancer Biol Ther; 2006 Feb; 5(2):180-8. PubMed ID: 16357524 [TBL] [Abstract][Full Text] [Related]
11. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282 [TBL] [Abstract][Full Text] [Related]
12. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [TBL] [Abstract][Full Text] [Related]
13. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959 [TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated gene transfer of caspase-8 sensitizes human adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand. Yasui H; Adachi M; Hamada H; Imai K Int J Oncol; 2005 Feb; 26(2):537-44. PubMed ID: 15645141 [TBL] [Abstract][Full Text] [Related]
15. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242 [TBL] [Abstract][Full Text] [Related]
16. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766 [TBL] [Abstract][Full Text] [Related]
17. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells. Jacob D; Schumacher G; Bahra M; Davis J; Zhu HB; Zhang LD; Teraishi F; Neuhaus P; Fang BL World J Gastroenterol; 2005 May; 11(17):2552-6. PubMed ID: 15849810 [TBL] [Abstract][Full Text] [Related]
18. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Bernt KM; Ni S; Gaggar A; Li ZY; Shayakhmetov DM; Lieber A Mol Ther; 2003 Nov; 8(5):746-55. PubMed ID: 14599807 [TBL] [Abstract][Full Text] [Related]